多巴胺转运体PET配体[(18)F]β-CFT在评估帕金森病残疾程度中的应用价值。
Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.
作者信息
Rinne J O, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O
机构信息
Department of Neurology, University of Turku; Turku PET Centre, Turku, Finland.
出版信息
J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):737-41. doi: 10.1136/jnnp.67.6.737.
OBJECTIVES
The usefulness of a novel dopamine transporter PET ligand, [(18)F]beta-CFT in assessing disability in Parkinson's disease was studied.
METHODS
Twenty seven patients with Parkinson's disease in different disability stages (of which nine were patients with early disease) and nine healthy controls were studied. The regions of interest were drawn on a magnetic resonance image resliced according to the PET image.
RESULTS
There was a significant reduction in [(18)F]beta-CFT uptake in the posterior putamen (to 18% of the control mean, p<0.00001), anterior putamen (28%, p<0.00001), and caudate nucleus (51%, p<0.00001) in the total population of patients with Parkinson's disease. The reduction in [(18)F]beta-CFT uptake was more pronounced with more severe disability of the patients, the correlations between the total motor score of the unified Parkinson's disease rating scale (UPDRS) and [(18)F]beta-CFT uptake being significant in the posterior putamen (r=-0.62 p=0.0005), anterior putamen (r=-0.64, p=0.0003), and the caudate nucleus (r=-0.62, p=0.0006). There was a significant negative correlation with putaminal [(18)F]beta-CFT uptake and the hypokinesia and rigidity scores, but not with the tremor score of the UPDRS motor part. In nine patients with early disease and without any antiparkinsonian medication the reduction in the [(18)F]beta-CFT uptake (average of ipsilateral and contralateral side) was reduced in the total putamen to 34% of the mean control value (p<0.00001). The corresponding figures in the other brain areas were: posterior putamen 21% (p<0.00001), anterior putamen 43% (p<0.00001), and caudate nucleus 76% (p<0.01). The reductions in [(18)F]beta-CFT uptake were more severe in the contralateral than in the ipsilateral side. Individually, [(18)F]beta-CFT uptake in the putamen in all patients was below 3 SD from the control mean.
CONCLUSIONS
[(18)F]beta-CFT is a sensitive marker of nigrostriatal dopaminergic dysfunction in Parkinson's disease and can be used in the diagnosis, assessment of disease severity, and follow up of patients.
目的
研究新型多巴胺转运体PET配体[（18）F]β-CFT在评估帕金森病残疾程度方面的效用。
方法
对27例处于不同残疾阶段的帕金森病患者（其中9例为早期患者）和9名健康对照者进行研究。感兴趣区域是在根据PET图像重新切片的磁共振图像上绘制的。
结果
在帕金森病患者总体中，[（18）F]β-CFT在后壳核（降至对照均值的18%，p<0.00001）、前壳核（28%，p<0.00001）和尾状核（51%，p<0.00001）的摄取量显著降低。患者残疾程度越严重，[（18）F]β-CFT摄取量的降低越明显，统一帕金森病评定量表（UPDRS）的总运动评分与[（18）F]β-CFT摄取量之间的相关性在后壳核（r=-0.62，p=0.0005）、前壳核（r=-0.64，p=0.0003）和尾状核（r=-0.62，p=0.0006）中显著。壳核[（18）F]β-CFT摄取量与UPDRS运动部分的运动减少和强直评分呈显著负相关，但与震颤评分无关。在9例未服用任何抗帕金森病药物的早期患者中，壳核总体[（18）F]β-CFT摄取量（同侧和对侧平均值）降至对照均值的34%（p<0.00001）。其他脑区的相应数据为：后壳核21%（p<0.00001）、前壳核43%（p<0.00……此处原文有误，应为p<0.00001）和尾状核76%（p<0.01）。[（18）F]β-CFT摄取量的降低在对侧比同侧更严重。所有患者壳核中的[（18）F]β-CFT摄取量均低于对照均值的3个标准差。
结论
[（18）F]β-CFT是帕金森病黑质纹状体多巴胺能功能障碍的敏感标志物，可用于患者的诊断、疾病严重程度评估和随访。
Zotero 插件